Learn Why The Bull Case For Perrigo Stock Could Change Following Weaker 2026 Guidance

Simply Wall St.11-06

Perrigo Company plc reported third quarter 2026 sales of US$988.6 million and a net loss of US$27.5 million, and outlined weaker full year 2026 guidance alongside the planned treatment of its infant ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681833028?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743","is_english":true,"pubTime":"2026-11-06 11:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681833028","market":"nz","top_or_hot":-1,"title":"Learn Why The Bull Case For Perrigo Stock Could Change Following Weaker 2026 Guidance","media":"Simply Wall St.","content":"<div>\n<p>Perrigo Company plc reported third quarter 2026 sales of US$988.6 million and a net loss of US$27.5 million, and outlined weaker full year 2026 guidance alongside the planned treatment of its infant ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-prgo/perrigo/news/learn-why-the-bull-case-for-perrigo-stock-could-change-follo\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Learn Why The Bull Case For Perrigo Stock Could Change Following Weaker 2026 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLearn Why The Bull Case For Perrigo Stock Could Change Following Weaker 2026 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-06 11:44 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-prgo/perrigo/news/learn-why-the-bull-case-for-perrigo-stock-could-change-follo><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Perrigo Company plc reported third quarter 2026 sales of US$988.6 million and a net loss of US$27.5 million, and outlined weaker full year 2026 guidance alongside the planned treatment of its infant ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-prgo/perrigo/news/learn-why-the-bull-case-for-perrigo-stock-could-change-follo\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BFMHRM44.USD","symbol_name":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-prgo/perrigo/news/learn-why-the-bull-case-for-perrigo-stock-could-change-follo","article_id":"2681833028","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6121000-choice1-card/1788949577743"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-prgo/perrigo/news/learn-why-the-bull-case-for-perrigo-stock-could-change-follo","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2681833028","pubTimestamp":1793936650,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BBailey PembertonNovember 6, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BFMHRM44.USD":"NEUBERGER BERMAN GLOBAL EQUITY MEGATRENDS \"A\" (USD) ACC","PRGO":"百利高","BK4007":"制药"},"translate_title":"了解为什么 Perrigo 股票的牛市在 2026 年指引走弱后可能会发生变化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRGO":1},"content_text":"Perrigo Company plc reported third quarter 2026 sales of US$988.6 million and a net loss of US$27.5 million, and outlined weaker full year 2026 guidance alongside the planned treatment of its infant formula divestiture as discontinued operations. The divestiture of the infant formula unit and a guided year on year net sales decline of 4.6% to 5.7% point to a sharper focus on core over the counter health products, although this brings nearer term revenue pressure. We will now look at how Perrigo's investment narrative could shift in light of the deeper 2026 sales guidance cut.  Spot under-pressure healthcare stories like Perrigo alongside other potential turnaround candidates with resilient balance sheets in our hand picked list of solid balance sheet and fundamentals (25 results). AdvertisementPerrigo Investment Narrative Recap To own Perrigo, you need to believe the consumer self care pivot can offset current pressure on demand and pricing. In the near term, the story revolves around stabilising core OTC categories after the infant formula sale and translating market share gains into steadier revenue. The weaker 2026 net sales outlook puts more weight on execution of that refocus. The key short term catalyst is whether Perrigo can turn those share gains and cost programs into cleaner margins despite softer U.S. and European consumption. The biggest risk is that volume driven private label exposure and ongoing category weakness could keep sales drifting lower while the business remains loss making. The clearest development tied to this thesis is the new 2026 guidance, which calls for all in net sales to decline 4.6% to 5.7%. That update, paired with a US$27.5 million quarterly loss and a US$351.6 million loss for the first nine months of 2026, keeps investors focused on the path to consistent profitability. The revised outlook follows the infant formula divestiture and reflects retailer inventory patterns and a softer European consumer backdrop. Those factors directly affect the timing of any potential earnings recovery catalyst. At the same time, the US$0.29 quarterly dividend, recently affirmed for December, draws attention to dividend coverage as a live risk while cash generation remains under pressure. Perrigo's current earnings sit at a loss of US$1.7b, while analysts forecast earnings of US$86.4 million on revenues of US$4.2b by 2029. This implies a very large earnings improvement in dollar terms as profit margins are expected to move from a loss-making 41.1% today to a positive 2.0%, with revenue described as remaining fairly flat over that period.\nUncover why Perrigo's fair value indicates a 15% potential upside to its current price, which could narrow quickly. NYSE:PRGO 1-Year Stock Price Chart Exploring Other Perspectives For a very different angle, some of the most optimistic analysts were leaning hard on Perrigo’s cost savings story. Before this weaker 2026 guidance, they were pencilling in revenue of about US$4.2b and earnings near US$131.9 million by 2029. You should expect those views to evolve and compare these upbeat assumptions with your own. Explore 3 other Perrigo fair value estimates, including one that suggests as much as 156% upside from the current price! Form Your Own Verdict Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.  A great starting point for your Perrigo research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. See our latest analysis for Perrigo. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Perrigo's overall financial health at a glance.  Looking for more investment ideas beyond Perrigo? If Perrigo has sharpened your focus on balance sheets, earnings quality, and realistic expectations, it can be useful to set it alongside a wider watchlist built around the traits you care about most.  If capital protection comes first for you, start by scanning 32 resilient stocks with low risk scores that keep risk scores in check while still offering equity upside. If you want income to matter as much as price charts, sort through 6 dividend fortresses that pair 5%+ yields with an emphasis on resilience. If you prefer to hunt earlier in the story rather than after the crowd arrives, narrow your search with 21 high quality undiscovered gems that combine strong fundamentals with lower market attention.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681833028","isCrawlerRequest":true}